Waterdrop Inc. Announces Third Quarter 2025 Unaudited Financial Results, Net profit rises 60.1% year-on-year

Waterdrop Inc. Announces Third Quarter 2025 Unaudited Financial Results, Net profit rises 60.1% year-on-year

BEIJING, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the three...

Synera Receives Frost & Sullivan's 2025 Global AI Agents for Engineering Transformational Innovation Leadership Recognition for Excellence in Engineering Digitalization and Automation

Synera Receives Frost & Sullivan's 2025 Global AI Agents for Engineering Transformational Innovation Leadership Recognition for Excellence in Engineering Digitalization and Automation

Recognized for redefining engineering automation through AI-powered innovation that enhances efficiency, accelerates product development, and drives measurable operational cost reduction. BREMEN, Germany and SAN ANTONIO, Dec. 3, 2025 /PRNewswire/ --...

Waterdrop Inc. Announces Third Quarter 2025 Unaudited Financial Results

Waterdrop Inc. Announces Third Quarter 2025 Unaudited Financial Results

BEIJING, Dec. 3, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial...

S3 Connected Health Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Medical Device Connectivity

S3 Connected Health Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Medical Device Connectivity

Recognized for pioneering advancements that redefine medical device connectivity, accelerate home-based care, and deliver transformative value across global healthcare ecosystems. SAN ANTONIO, Dec. 3, 2025 /PRNewswire/ -- Frost & Sullivan is...

vHive Launches Real-Time Solution to Validate As-Built Installations for MNOs

vHive Launches Real-Time Solution to Validate As-Built Installations for MNOs

NEW YORK, Dec. 3, 2025 /PRNewswire/ -- vHive, a global leader in infrastructure digitization, announces the launch of On-Site Validation, the first real-time field verification solution that ensures antenna installations match modification plans...

A New Chapter in Bilingual Excellence: YK Pao School Hong Kong Appoints its Founding Head

A New Chapter in Bilingual Excellence: YK Pao School Hong Kong Appoints its Founding Head

HONG KONG, Dec. 3, 2025 /PRNewswire/ -- In a significant milestone in its founding, YK Pao School Hong Kong today announces the appointment of Mrs. Cathy Braithwaite as its Founding Head. This appointment marks the next step in realising a visionary...

Beep Receives Frost & Sullivan's 2025 North American Technology Innovation Leadership Recognition for Excellence in Scalable, Service-Oriented Autonomous Mobility Solutions

Beep Receives Frost & Sullivan's 2025 North American Technology Innovation Leadership Recognition for Excellence in Scalable, Service-Oriented Autonomous Mobility Solutions

Beep is honored for combining innovation, operational efficiency, and customer trust to advance autonomous shuttle adoption across public and private transit networks SAN ANTONIO, Dec. 3, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to...

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases OMLYCLO®...

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and...

Cellid Announces Two New Reference Designs for Next-Generation AR Glasses

Cellid Announces Two New Reference Designs for Next-Generation AR Glasses

Cutting-edge wireless AR glasses enabled by proprietary optical technology and the latest waveguide innovations TOKYO, Dec. 2, 2025 /PRNewswire/ -- Cellid Inc., a developer of displays and spatial recognition engines for next-generation AR glasses,...

  • 1
  • ...
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • ...
  • 145
  • menu
    menu